BeiGene and Ambrx Enters into a Worldwide Research and Development Collaboration to Develop Novel Biologics

Shots:

• Ambrx will receive $475M as a total deal value including $29M upfront for research & other programs, $446M as development, regulatory & commercial milestones and royalties on global sales. BeiGene to get WW development and commercialization rights for all products
• The focus of an agreement is to develop next-generation biologics by using Ambrx’s Expanded Genetic Code technology (ReCODE) & (EuCODE) with BeiGene’s expertise and resources
• Ambrx also collaborated with Bristol-Myers Squibb, Astellas, Elanco and ZMC to develop drug candidates using its technology

Click here to read full press release/ article | Ref: Ambrx | Image: Drug Development Technology